prakash nallathamby

1.2K posts

prakash nallathamby banner
prakash nallathamby

prakash nallathamby

@prakashdn

Biomedical Engineer - Therapeutics to combat multidrug resistance. Views are mine.

Notre Dame, IN Katılım Haziran 2009
835 Takip Edilen310 Takipçiler
prakash nallathamby retweetledi
Ren
Ren@renstocks_·
I have to agree with @leopoldasch – $NBIS and $SNDK seem like the best bets going forward, so I’m building my portfolio around these names. Did a deep dive on $SNDK, helpful for all types of investors. Go check it out on Substack. You can claim your free paid post and build your own conviction. I won’t spoil it for you… but you kinda know where this is headed ⚡️ open.substack.com/pub/rensub/p/s…
Ren tweet mediaRen tweet media
Leopold Aschenbrenner@leopoldasch

Virtually nobody is pricing in what's coming in AI. I wrote an essay series on the AGI strategic picture: from the trendlines in deep learning and counting the OOMs, to the international situation and The Project. SITUATIONAL AWARENESS: The Decade Ahead

English
4
10
210
39.1K
prakash nallathamby retweetledi
Samuel Hume
Samuel Hume@DrSamuelBHume·
This week in medicine 1. A synthetic lethal approach adds to RAS inhibition in pancreatic cancer 2. A potentially best-in-class ulcerative colitis drug 3. Discovery of a defined autoimmune subtype of inflammatory bowel disease 4. Genetic therapies for sickle cell keep working 5. More data on muscle-sparing weight loss
English
2
13
121
10.7K
prakash nallathamby retweetledi
nini
nini@nini_incrypto_·
下一只十倍会是谁呢? 第一波(半导体):NVDA、ARM、AMD、AVGO, INTC, TSM 第二波(存储芯片):MU、WDC、STX、SNDK 第三波(光模块/光通信):NOK、LITE、COHR、AAOI, GLW, CIEN, MRVL 第四波(AI算力&数据中心):IREN、CIFR、WULF、CORZ, NBIS, CRWV, SMCI, DELL 第五波(网络设备):ANET、AVGO、MRVL、CSCO 第六波(电源/电网/温控):VRT、ETN、GEV、CEG, SMR, OKLO, VST 第七波(原材料/稀土):MP、USAR、UUUU、FCX、AA 第八波(太空航天):ASTS、RKLB、LUNR、PL 第九波(终局应用):TSLA、PLTR、SYM、SERV
中文
78
455
2.5K
495.3K
prakash nallathamby retweetledi
Michael | Hypermarkets
Michael | Hypermarkets@itsmichaelluu·
$SPCX shares are priced at $135 for its $2 trillion IPO. Its return is 100x-200x by 2035. These 20 companies will benefit the most: 1. $BKSY ~$34 AI-ready Earth observation satellites feed SpaceX orbital intelligence layer. 2. $SPIR ~$20 Space data analytics monetizing SpaceX's growing orbital constellation. 3. $ACHR ~$5 Air mobility networks integrate with Starlink's low-latency infrastructure. 5. $SATL ~$7 High-resolution imaging complements SpaceX orbital AI compute constellation data. 6. $VIAV ~$50 Optical networking components critical for Starlink ground station upgrades. 7. $OUST ~$40 Sensor fusion tech supports SpaceX booster catch reusability automation. 8. $GILT ~$15 Satellite ground infrastructure scales alongside Starlink enterprise deployments. 9. $POET ~$11 Optical interposer chips slash data center power costs inside COLOSSUS AI cluster. 10. $ARQQ ~$12 Quantum encryption securing Starshield government classified orbital networks. 11. $TWST ~$74 Synthetic biology tools accelerate SpaceX long-term Mars life support research. 12. $LUNR ~$30 NASA lunar lander tech directly supports SpaceX Moon base buildout. 13. $AEVA ~$24 LiDAR sensors enable autonomous Starship landing and booster catch precision. 14. $KTOS ~$60 Defense tech partner powering Starshield national security satellite contracts. 15. $IONQ ~$58 Quantum compute layer powering next-gen orbital AI satellites. 16. $RDDT ~$178 Real-time social data feeds Grok's truth-seeking AI via X integration. 17. $RKLB ~$115 Small payload launch fills exact gaps Falcon can't efficiently serve. 18. $ASTS ~$97 Direct-to-phone satellite broadband. Starlink's closest competitor and partner. 19. $MTSI ~$375 RF semiconductors power Starlink phased-array antenna signal processing. 20. $BWXT ~$200 Nuclear propulsion R&D aligns with SpaceX Mars mission power requirements. I'm definetly a buyer of $SPCX IPO and want to get it super cheap. ♻️ RESHARE this post and write 1 comment, I'll DM you the PRICE I want to buy $SPCX at this month.
Michael | Hypermarkets tweet media
English
342
1.1K
6.6K
1.9M
prakash nallathamby retweetledi
Samuel Hume
Samuel Hume@DrSamuelBHume·
Synthetic lethality is the concept that attracted me to cancer biology >10 years ago. Two defects that are tolerable separately are lethal together – this is useful to target cancer cells (which often inactivate genes as they transform) while sparing normal cells. There's still only one synthetic lethal interaction to reach approval and clinical use (PARP-BRCA), but PRMT5-MTAP would make a very welcome second!
Samuel Hume tweet media
Adam Feuerstein ✡️@adamfeuerstein

‘Synthetic lethality’ could trigger another round of biotech M&A $RVMD $TNGX $BMY $ERAS statnews.com/2026/06/11/syn…

English
5
19
117
17.2K
prakash nallathamby retweetledi
Rosanna Prestia, MBA
Rosanna Prestia, MBA@RosannaInvests·
🚨Everyone is still buying the chips. The bottleneck already moved. A GPU that computes in nanoseconds and waits microseconds for data is a stranded asset. At 1.6T speeds, copper runs out of physics. The constraint on AI is no longer how fast you can think. It's how fast you can move what you thought. Jensen has now said it twice in three months. At GTC in March: "Is copper going to still be important? The answer is yes... Are you going to scale up optical? Yes. Are you going to scale out optical? Yes... We need a lot more capacity for copper. We need a lot more capacity for optics. We need a lot more capacity for CPO." Last week at Computex, on Marvell's stage: "Optics where you must, copper where you can." Then he called Marvell the next trillion-dollar company and the optical complex repriced within days. The same keynote put a date on the handoff: 200G per lane is the last generation where copper is sufficient. After that, optics takes the rack. Translation: not copper OR light. Copper now, light next, unprecedented amounts of both. 🔥 The chain is unavoidable: AI tokens are profitable → more GPUs → more bandwidth → copper hits its wall → photonics becomes the chokepoint. And the smart money stopped debating. Follow the closed deals: → $NVDA has committed at least $6.5B to photonics in three months: $2B into Lumentum, $2B into Coherent, a $500M stake in Corning, and a piece of Ayar Labs' $500M round. Direct investments to secure its own light supply. → $MRVL paid $3.25B for Celestial AI, up to $5.5B with milestones, to build what its CEO calls a silicon photonics powerhouse. → $CRDO closed DustPhotonics two weeks ago. Ciena bought CPO startup Nubis for $270M. North of $10B of strategic capital locked up one supply chain in under a year. Capital like that doesn't chase a theme. It secures a bottleneck. LAYER 1: WAFER. Every laser starts as a crystal. 🟠 $AXTI: the InP substrate leader. The first chokepoint in the stack. 🟡 $IQE: compound-semi epiwafers feeding the laser makers. Speculative, but structurally upstream. LAYER 2: LIGHT. Photons don't make themselves. 🟠 $LITE: revenue +90% YoY last quarter to $808M. EML shipments doubled and management says demand still exceeds supply across EMLs, pump lasers, and transceivers. NVIDIA just wired them $2B. OCS backlog past $400M plus a multi-hundred-million CPO order for 2027. 🟢 $SIVEF (Stockholm: SIVE): the external light source. CPO does not emit its own light. Every optical engine needs a continuous-wave InP laser feeding it, and that is the layer you cannot engineer around. ELS modules with POET hit production readiness end of this year. Disclosure: long. 🟣 $POET: the optical engine wildcard. Its Optical Interposer pairs with Sivers' lasers on external light sources for CPO, with a LITEON module deal stacked on top. Binary commercialization, real architecture. LAYER 3: OPTICS AND MODULES. Where light meets the rack. 🟠 $COHR: the volume anchor in transceivers, holding NVIDIA's other $2B check. 🔵 $AAOI: Q1 revenue +51% to a record $151M, datacenter revenue more than doubled, $124M of 800G orders plus a $200M+ 1.6T order in hand. Scaling Texas capacity toward 500K+ units a month by year-end, targeting $1B+ revenue this year. Domestic supply while everyone fights over offshore. Disclosure: long. 🟠 $FN: the foundry of optics. When Fabrinet is building, the orders already exist. THE INTERCONNECT: the layer the rack cannot route around. 🔵 $CRDO: just closed DustPhotonics. SerDes → DSP → silicon photonics → system integration, one company, 800G through 3.2T. Electrical AND optical, end to end. FY26 revenue tripled to $1.34B at 68% gross margin. The toll booth on both roads. Disclosure: long. 🟠 $MRVL: $3.25B for Celestial AI, and Jensen's trillion-dollar nod on the Computex stage. 🟠 $AVGO: switch silicon, optical DSPs, CPO engines. They define the socket. 🟠 $ANET: the AI spine. 100K-GPU clusters get stitched together in light. LAYER 4: PACKAGING, FIBER, FOUNDRY. Where photons get industrialized. 🔵 $TSEM: the neutral silicon photonics foundry. Prints wafers for whoever wins. 🟣 $LPKF: glass-substrate packaging for glass-based CPO. Real technology, binary commercialization. 🟠 $GLW: AI racks demand several times the fiber density of legacy cloud, and NVIDIA just took a $500M stake. Corning sells density. LAYER 5: TEST AND THE ANALOG UNDERLAYER. Complexity is a tax paid in validation. 🔵 $AEHR: silicon photonics test, ramping with the cycle. ' 🔵 $VIAV: every 800G and 1.6T transceiver gets validated before it ships. The gate the market prices like an accessory. 🔵 $SMTC: the drivers and TIAs that fire the lasers. Sits directly under the LPO trade. 🔵 $MTSI: the high-speed analog behind 1.6T engines. 🟠 $CIEN: transport. Even long-haul is buying light. 💡The counter-thesis, because every map needs one. The honest debate on this stack is whether these are genuine bottleneck assets or cyclical optics suppliers enjoying peak demand at peak multiples. Lumentum's May print showed +90% growth with the stock up roughly 1,400% over the prior year at a triple-digit trailing multiple. That is a price for perfection. Most of these names live or die on a handful of hyperscaler capex lines, and one digestion quarter hits the whole stack at once. CPO timing has already slipped once. Architecture risk is real: LPO, CPO, and stretched copper are still fighting for the same sockets. The cycle is real. So is the gravity. 🔥 But the bears have to explain one thing: $NVDA, $MRVL, $CRDO, and $CIEN just spent over $10B securing this supply chain with their own balance sheets. The people with the best information are paying up for the layers. The market owns the top of this stack. The asymmetry is at the edges: wafer, light, packaging, test. Own the layers, not the logo. Bookmark this for the weekend. Then tag the one investor you know who's still all compute and no interconnect. 👀
Rosanna Prestia, MBA tweet media
English
34
149
830
79.5K
prakash nallathamby retweetledi
Ren
Ren@renstocks_·
I was looking back to where I first found the most relevant information before I went in heavy on photonics at the beginning of the year. I keep coming back to this post from Gaetano back in December of 2025. Gaetano has been one of my top 5 sources of clear and objective information here on X. I bought $LITE around 350 and $AAOI around 40 because I like to talk to the people who are most knowledgeable on the subject, the ones who are not only early but are right now in the money. Gaetano has been that for me, grade A content on the photonics sector, and he is now researching heavily on Physical AI. If you want to know more about the future themes that are going to be big 6 months from now, drop @crux_capital_ a follow. Stand-up guy, great researcher and investor.
Gaetano@crux_capital_

🚨There is a ton of momentum building in photonics right now. $POET $MRVL $LITE $COHR $AAOI $TSEM $CIEN Every part of the stack is heating up, and management teams have basically spent the last month broadcasting the same story. Let’s dig into some of the recent bits I’ve been watching... $LITE Q1 revenue up 58% YoY to $533.8M with next quarter guided to ~$650M, hitting their mid-2026 target two quarters early. Management pointed to cloud-optics demand running well above supply with transceivers, optical circuit switches, and early co-packaged optics driving the next leg. $COHR “AI data centers and communications remain strong long-term growth drivers.” They just posted $1.58B in revenue, +17% YoY, and highlighted accelerating hyperscale DCI demand across their ZR / ZR+ lineup and their 400G / 800G ramps. $MRVL “AI infrastructure is transforming faster than ever.” “We’re going to have a silicon-photonics powerhouse at Marvell when this is all done.” The $3.25B Celestial AI acquisition comes with a modeled $500M run-rate by FY28 and $1B by FY29 Celestial AI “Marvell is the ideal home for our Photonic Fabric… the scale and customer reach to take this platform into high-volume production.” $POET Their optical-engine technology is already designed into Celestial AI’s Photonic Fabric, the same platform Marvell just paid $3.25B to acquire. As AI systems move toward denser, more integrated optical engines, POET sits directly inside one of the most advanced photonics architectures in the market - now part of Marvell’s silicon-photonics roadmap. $AAOI Revenue up 82% YoY. They’re on track to build what they believe will be the largest domestic production capacity for 800G and 1.6T transceivers by year-end, roughly 35k parts per month, all inside their Texas footprint. $TSEM Expecting silicon-photonics revenue to more than double off last year’s base. They’re investing $300M into photonics and AI-focused expansion and calling for ~75% growth in that segment. $CIEN “We delivered record orders. Cloud and AI providers continue to invest in high-capacity optical transport.” DCI and long-haul momentum continue to show up directly in the numbers. ... But you can’t just look at the transceiver and laser makers. Some of the clearest signals are coming from the companies building the architecture and the supply chain behind it. $AVGO AI revenue moving from ~$11B to $20B+. They’re doubling down on silicon photonics Controlling the switch silicon, the optical DSP, and the optical engines at the heart of modern AI racks. If you’re bullish on photonics, this is one of the companies defining the socket. $ANET Building the “AI spine.” Their Ethernet-based AI networking platform relies entirely on high-speed optics to stitch together massive GPU clusters 100k-GPU scale and up. As clusters get larger, copper falls out of the system and optics takes over. $FN Record ~$980M in revenue. They manufacture optical engines for some of the largest players in the space - $NVDA, $LITE, $COHR, and others. When Fabrinet says demand is exceptional, it means the orders are already in the building. $GLW Optical Communications revenue up 33% YoY. AI racks require roughly 10x the fiber density of legacy cloud racks. Corning is supplying the physical layer that makes 800G and 1.6T optics viable at scale. $SMTC Solid print tied to growing traction in Linear Pluggable Optics (LPO). They sit in the analog layer, drivers and TIAs that fire the lasers, and are positioned directly under the 800G / 1.6T cycle. $MTSI Revenue up 30% YoY. They build the high-speed analog components that sit behind next-gen optical engines and are essential for 1.6T designs. .... This is all widespread. It’s lasers, transceivers, optical switches, silicon photonics, scale-up fabrics, DCI, long-haul transport, Ethernet AI spines, fiber density, and the analog chips behind every laser all moving in the same direction. If you’re tracking AI infrastructure, photonics continues to gain strength week after week.

English
25
25
617
207.3K
prakash nallathamby retweetledi
Raghav Wadhwa
Raghav Wadhwa@raghavwadhwa·
India sells one in five generic pills on the planet. But in 30 years it had never invented a brand new medicine and taken it through the US FDA on its own. A mid-cap pharma company just did, with a drug built to kill the bacteria that no longer respond to anything else. On 1 June 2026, Wockhardt's Zaynich (cefepime + zidebactam) became the first new chemical entity fully discovered and developed by an Indian company to win US FDA approval. Not a copy of an expired molecule. A first-in-class drug. It targets the part of medicine that is quietly breaking: drug-resistant bacteria. 🔹 AMR was linked to ~2.97 lakh deaths attributable to resistance in India in 2019, and over 10 lakh associated deaths (GBD/Lancet). Globally it kills more people a year than HIV and malaria. 🔹 These are the infections where last-line antibiotics have stopped working. What the FDA actually cleared (precision matters): 🔹 Indication: complicated urinary tract infections including kidney infection (pyelonephritis), from susceptible Gram-negative bugs. 🔹 Phase 3 ENHANCE-1: composite cure of 89.0% vs 68.4% for meropenem, the current standard. On clinical cure alone, 96.8%, which Wockhardt says is the highest among novel antibiotics the FDA has cleared in over a decade. 🔹 It uses a beta-lactam enhancer mechanism that hits multiple bacterial targets at once, which is why resistant strains struggle against it. The opportunity: 🔹 US course pricing roughly $10,000 to $15,000 for a 7 to 10 day treatment. India price not yet announced, guided at 15 to 25% of US. 🔹 India addressable pool ~2.5 lakh patients. Revenue starts meaningfully FY28, FY29 is the "hockey stick" year per the chairman. It is self commercialising in the US instead of licensing out, to keep the full value. The company behind it is on a sharp upswing. In FY26 Wockhardt swung back to profit (PAT ₹199 cr vs a ₹57 cr loss the year before), revenue rose to ₹3,373 cr, and EBITDA margin expanded to 18.7%. It now holds five novel antibiotics through Phase 3, with Zaynich the first to cross the FDA line. The deeper signal: India's pharma identity may be shifting from pharmacy of the world built on volume and generics, to originating molecules the world has never seen. Zaynich is the first proof point. 📌Disclaimer: Educational purposes only, not a buy/sell recommendation
English
7
50
273
45.2K
prakash nallathamby retweetledi
Mindaugas Galvosas, MD
Going through some ASCO abstracts, seems like the trend in personalized cancer vaccines is generally vaccine + pembrolizumab Moderna’s trial in resected melanoma pts did it, another example in glioblastoma here asco.org/abstracts-pres…
English
0
1
2
155
prakash nallathamby retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
🩸 MY TOP 10 TRIALS TO WATCH AT #EHA2026 🔬 MYELOID MALIGNANCIES 1️⃣ HOVON 156 / AMLSG 28-18 Gilteritinib vs Midostaurin in FLT3-mutated AML ⭐ Perhaps the most important AML readout of EHA2026. 2️⃣ SENTRY Selinexor + Ruxolitinib in frontline myelofibrosis ⭐ Potential new standard if survival signals mature. 🩸 LYMPHOMA 3️⃣ EPCORE DLBCL-1 Epcoritamab vs chemotherapy in R/R DLBCL ⭐ Landmark chemo-free challenge. 4️⃣ EPCORE NHL-1 Long-term durability of epcoritamab in LBCL & FL ⭐ How durable are bispecific responses? 5️⃣ Glofitamab 5-Year Follow-Up ⭐ Can fixed-duration bispecific therapy deliver durable cures? 6️⃣ Pola-R-ICE ⭐ ORR 88%, CR 56% in transplant-eligible R/R DLBCL. Important where CAR-T access remains limited. 💥 MULTIPLE MYELOMA 7️⃣ Immuno-PRISM Teclistamab in high-risk smoldering myeloma. ✅ CR/sCR: 73% vs 0% ✅ uMRD negativity: 81% ✅ 2-year PFS: 92% vs 51% ⭐ The most fascinating dataset of EHA2026. 8️⃣ MajesTEC-3 Teclistamab + Daratumumab in high-risk RRMM ⭐ Can bispecifics overcome aggressive biology? 9️⃣ MONUMENTAL-3 Talquetamab-based triplets vs DPd ⭐ GPRC5D moves earlier. 🔟 BelaDRd Belantamab moves into frontline myeloma. ⭐ Can BCMA ADCs find a place in newly diagnosed disease? Which EHA2026 presentation are you watching most closely? #EHA2026 #MultipleMyeloma #AML #Lymphoma @OncoAlert @Larvol @ASCO @EHA_Hematology
Dr Rishabh Jain tweet media
English
0
17
67
10.9K
prakash nallathamby retweetledi
Samuel Hume
Samuel Hume@DrSamuelBHume·
To get an idea what the drugs of the future might look like, it's useful to look at Nature, where the biggest pre-clinical discoveries are published. Here's what there is today: 1. A molecular glue degrader for BRAF-mutant colorectal cancer (that might help overcome resistance to BRAF inhibitors). 2. A 'pulsatile' FXR agonist for liver disease – MASH, PBC, PSC – that could avoid the issues of the current FXR agonists. 3. Structures of a sodium channel (Nav1.6), which could be used to design better drugs for epilepsy or pain.
Samuel Hume tweet mediaSamuel Hume tweet mediaSamuel Hume tweet media
English
0
15
92
15.9K
prakash nallathamby retweetledi
Samuel Hume
Samuel Hume@DrSamuelBHume·
Here's how it works:
Samuel Hume tweet media
English
1
2
12
1.8K
prakash nallathamby retweetledi
Samuel Hume
Samuel Hume@DrSamuelBHume·
Daraxonrasib quite rightly stole the show at ASCO, but there were lots of data on innovative approaches in pancreatic cancer To highlight some others First, this combination therapy: a PD1/CTLA4 bispecific + multikinase inhibitor + chemotherapy (4 complete responses, 76% objective response rate)
Samuel Hume tweet media
Samuel Hume@DrSamuelBHume

I spent the last week in beautiful Chicago at the biggest cancer conference in the world Here's the most exciting new science that was presented: substack.com/home/post/p-20…

English
7
25
133
19.5K
prakash nallathamby retweetledi
Ansu Satpathy
Ansu Satpathy@Satpathology·
A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR. @vincentzliu and @CalebLareau solved it! We developed Mitotrek using scATAC-seq + mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry. @10xGenomics @parkerici @CancerResearch @TheMarkFdn cell.com/cancer-cell/fu…
English
8
99
361
34.4K
prakash nallathamby retweetledi
Ruslan Rust
Ruslan Rust@rust_ruslan·
A multimodal perturbation atlas of 1,000 pooled CRISPR knockouts in A549 cells, profiled by fluorescence microscopy (39 live, 13 fixed markers), label-free phase imaging of the same live cells, and single-cell RNA sequencing (scRNA-seq) Totaling ~57 million single-cell profiles Preprint: biorxiv.org/content/10.648…
Ruslan Rust tweet media
English
2
22
85
8.1K
prakash nallathamby retweetledi
Michael | Hypermarkets
Michael | Hypermarkets@itsmichaelluu·
JENSEN HUANG DOING IT AGAIN IN TAIPEI, HE SAID THESE STOCKS ARE THE FUTURE: $NOW — AI agents run inside ServiceNow's enterprise software stack $CRWD — Security layer every AI factory must have running $PLTR — Turns AI agent outputs into real government/enterprise decisions $MSFT — Co-built the entire agentic PC platform with Jensen $TSM — Only company on earth that can build these chips AND HE HAS A DEAL WITH THESE ONES: $HPE — Builds and ships the physical AI factory server infrastructure $IREN — Owns the cheap power AI factories are desperately hungry for $CRWV — The cloud Jensen personally called out by dollar valuation $ARM — Every AI chip on the planet runs on ARM architecture $DELL — First to rack and deploy Vera Rubin in production $NVDA STILL SUPER EARLY SO DON'T MISS IT! ♻️ RESHARE this post and write 1 comment, I'll share my $HPE earnings play with you. It's tonight.
Michael | Hypermarkets tweet media
English
58
241
842
315.6K
prakash nallathamby retweetledi
Michael | Hypermarkets
Michael | Hypermarkets@itsmichaelluu·
In 1 year, $NBIS blew up 10x from $20 → $270. Recently, Leopold owns 6% stake in it. These 6 stocks under $30 can easily 10x: 1. $CIFR ~$23 $AMZN + $GOOG 15-year leases. $9.3B contracted. Analyst target: $70 2. $WULF ~$27 Google-backed Fluidstack deal. 1GW+ capacity. Analyst target: $80 3. $CORZ ~$28 CoreWea's landlord. $3.3B raised. 12-year $10B deal. Analyst target: $60 4. $BTDR ~$13 170% revenue growth. Owns its own AI chips. Analyst target: $50 5. $KEEL ~$6 Leopold accumulating. First colo deal Q3 2026 expected. Analyst target: $18 6. $HIVE ~$4 $30M AI cloud contracts signed. Liquid-cooled GPU clusters. Analyst target: $16 $NBIS $CRWV $IREN are Neocloud companies with deals with $MSFT $NVDA $GOOG $AMZN. They are providing compute to everyone. ♻️ RESHARE this post and write 1 comment, the best under $10 to buy and hold.
Michael | Hypermarkets tweet media
English
86
320
1.5K
416.5K
prakash nallathamby retweetledi
Oliver | MMMT Wealth (CPA)
Oliver | MMMT Wealth (CPA)@MMMTwealth·
$AAOI is very quickly becoming attractive again here at $12.7B market cap with 2027/2028 set to be huge ramp up years. -> Mid-2027: $471 per month in revenue. -> Fair to assume 2028 could be ~$6B (when added in CATV revenue as well). That means they've gone from $455M in revenue in FY25 -> potentially $6B in FY28... that's a 136% CAGR. Absurd ramp up in revenue. I ran a scan of those companies expected to hit more than 120% CAGR for the next 3 years and I think it's probably only these: $NBIS $ASTS $IREN $AUR $ONDS $USAR $NN Now $AAOI trades below 10x NTM sales right now. Guess which of the above trade below 10x sales? None.
Oliver | MMMT Wealth (CPA) tweet media
Oliver | MMMT Wealth (CPA)@MMMTwealth

$AAOI - THE BULL CASE (numbers) Let me show you the numbers: On the earnings call, management said if the hyperscaler demand plays out like expected, $AAOI could reach a data center revenue production rate equivalent to $378M per month by Q2 2027 which would equate to ~$4.5B in annualized run rate. They also guided for 40% gross margins by Q3. P/S: $LITE trades at 14x FY26 revenue with 76% expected growth with mid 20% operating margins. $AAOI trades at 7.0x FY26 revenue with 112% expected growth with anticipated 40% operating margins. So if $AAOI's AI/hyperscaler segment even gets to ~75% the multiple of LITE (which it should based on numbers), then $AAOI is deserving of 9x sales multiple on FY27 revenue, you're already looking at $40.5B in equity value right there. This is excluding the lower multiple segment of $AAOI which is CATV/Broadband which management expects ~$300M / year business. Give that a 2.0x sales multiple and you can add another $0.6B or so to the valuation. I don't think 9x sales multiple on the data center revs is unlikely at all so based on those numbers (if you believe management), then $AAOI is a great buy here. Even if you assume $AAOI achieves only 50% of the $4.5B annualized AI revenue run rate, and the multiples therefore compress to say 6x/7x you're still looking at potentially 2x from here. That's not the full story but that's a clear picture of the bull case looking purely at the numbers.

English
19
43
463
278.3K
prakash nallathamby retweetledi
Futurist | 10x Disruptive Stocks
Futurist | 10x Disruptive Stocks@futurist_lens·
My portfolio went up over 1,100% after I made one change: I started investing in disruptive themes. Photonics → $AAOI $AXTI $AEHR Space → $RKLB $ASTS $LUNR $PL Robotics → $OUST $VPG $AMBA AI Infrastructure → $NBIS $IREN Power Semis → $NVTS $VICR Defense → $ONDS $KTOS Energy → $VST $TE $BE That shift changed everything. Still trying to catch up with @DeepValueBagger
Futurist | 10x Disruptive Stocks tweet media
English
18
67
641
167.2K